Historically, green chemistry has had its roots in small molecule chemical process design. However, some of the boldest opportunities lie ahead in the peptide, oligonucleotide and large molecule modalities. With sustainability as a recognized priority across industries, the ACS Green Chemistry Institute Pharmaceutical Roundtable (GCIPR) has taken up the lead in advancing the enterprise with high aspirations.
Join Senior Research Advisor Michael Kopach of Eli Lilly and Company during this free interactive broadcast as he demonstrates why the opportunities for innovations in sustainable chemistry for peptides and oligonucleotide syntheses are much greater than for small molecule chemistry.
* If you are having technical difficulties viewing the video please try different internet browsers like Chrome, Firefox, and Explorer. If you still can not access the video please review the following computer prerequisites from our video hosting platform.
What You Will Learn
- How Peptide and Oligonucleotides are a growing therapeutic areas
- Why Process Mass Intensity (PMI) is > 3000 for most syntheses
- Why green chemistry will make a difference
- Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production—Article from The Journal of Organic Chemistry
- Introduction of a process mass intensity metric for biologics—Article from New Biotechnology